GARY PATOU - 17 Mar 2021 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role: Director
Signature: /s/ Cassandra Robinson, Attorney-in-fact
Issuer symbol: XENE
Transactions as of: 17 Mar 2021
Net transactions value: +$1,949
Form type: 4
Filing time: 04 Jun 2021, 19:20:26 UTC
Next filing: 10 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XENE	Common Shares	Small acquisition under Rule 16a-6	$1,949	+100		$19.49	100	17 Mar 2021	See Note	F1
holding	XENE	Common Shares						12,500	17 Mar 2021	See Note	F2
holding	XENE	Common Shares						23,573	17 Mar 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XENE	Stock Option (Right to Buy)	Award	$0	+10,000		$0.000000	10,000	03 Jun 2021	Common Shares	10,000	$18.56	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares acquired by the reporting person's son sharing the reporting person's household on the date of acquisition. Subsequent to the acquisition of the reported shares, the reporting person's son no longer shares a household with the reporting person and the reporting person no longer has a reportable beneficial interest in such shares. Subsequent ownership reports filed by the reporting person will not report these shares.
F2	By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
F3	One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.